Here are the 10-Q quarterly reports from Oncocyte Corporation (OCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCX filings page.
Insight Molecular Diagnostics Inc. (f/k/a Oncocyte) reported a noticeable uptick in commercial activity with net revenue of $518,000 for the quarter ended June 30, 2025 versus $104,000 a year earlier, and $2.656 million for the six months versus $280,000. Revenue growth was driven primarily by laboratory services and initial sales of the GraftAssureIQ kitted product.
Results show widening losses: a net loss of $9.742 million in the quarter (six-month loss of $16.413 million), as operating expenses rose to $10.192 million for the quarter, including a $2.804 million charge for the change in fair value of contingent consideration. Liquidity improved materially following a February 2025 registered offering that raised gross proceeds of approximately $29.1 million (net proceeds ~$28.7 million), leaving cash and cash equivalents of $24.3 million and combined cash plus restricted cash of $26.0 million at period end.
Operational and strategic developments include a corporate name and ticker change to IMDX and headquarters relocation to Nashville, an ongoing strategic partnership and investment with Bio-Rad, and a boosted Medicare reimbursement rate of $2,753 per result for GraftAssureCore. Significant noncurrent contingent consideration of $40.933 million and an accumulated deficit of $366.95 million remain on the balance sheet. Management concluded there is no substantial doubt about going concern for at least the next twelve months.